RM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russian Federation.
Ann Hematol. 2021 Mar;100(3):691-698. doi: 10.1007/s00277-021-04429-8. Epub 2021 Feb 2.
Immune checkpoint inhibitors (ICI) have demonstrated high therapeutic efficacy in relapsed or refractory classical Hodgkin lymphoma (r/r cHL). Nevertheless, despite the accumulated data, the question of the ICI therapy duration and efficacy of nivolumab retreatment remains unresolved. In this retrospective study, in a cohort of 23 adult patients with r/r cHL who discontinued nivolumab in complete response (CR), the possibility of durable remission achievement (2-year PFS was 55.1%) was demonstrated. Retreatment with nivolumab has demonstrated efficacy with high overall response rate (ORR) and CR (67% and 33.3% respectively). At the final analysis, all patients were alive with median PFS of 16.5 months. Grade 3-4 adverse events (AEs) were reported in 36% of patients, and there was no deterioration in terms of nivolumab retreatment-associated complications.
免疫检查点抑制剂 (ICI) 在复发或难治性经典霍奇金淋巴瘤 (r/r cHL) 中显示出了很高的治疗疗效。然而，尽管积累了大量数据，ICI 治疗持续时间和纳武利尤单抗再治疗疗效的问题仍未得到解决。在这项回顾性研究中，在 23 例因完全缓解 (CR) 而停用纳武利尤单抗的 r/r cHL 成年患者队列中，证明了持久缓解的可能性 (2 年 PFS 为 55.1%)。纳武利尤单抗再治疗显示出了疗效，总缓解率 (ORR) 和完全缓解率 (分别为 67%和 33.3%) 都很高。在最终分析时，所有患者均存活，中位 PFS 为 16.5 个月。36%的患者报告了 3-4 级不良事件 (AE)，并且在纳武利尤单抗再治疗相关并发症方面没有恶化。
